Filtered By:
Condition: Thrombosis
Countries: Netherlands Health

This page shows you your search results in order of date.

Order by Relevance | Date

Total 23 results found since Jan 2013.

Association between thrombus composition and stroke etiology in the MR CLEAN Registry biobank
ConclusionThrombus composition is significantly associated with stroke etiology, with an increase in RBC and a decrease in F/P raising the odds for a non-cardioembolic cause. No difference between composition of cardioembolic thrombi and of undetermined origin was seen. This emphasizes the need for more extensive monitoring for arrhythmias and/or extended cardiac analysis in case of an undetermined origin.
Source: Neuroradiology - April 15, 2023 Category: Radiology Source Type: research

EE568 Tenecteplase or Alteplase for Acute Ischemic Stroke? A Cost-Effectiveness Analysis
Alteplase is widely used as intravenous thrombolytic medication in acute ischemic stroke (AIS). However, tenecteplase, a genetically modified form of alteplase, has recently been shown to result in higher recanalization rates, improved functional outcome and a similar safety profile in AIS patients with large vessel occlusion (LVO) compared to alteplase. Accordingly, this study aims to evaluate the cost-effectiveness of 0.25mg/kg tenecteplase versus 0.9mg/kg alteplase for thrombolysis in AIS patients due to LVO from the Dutch healthcare payer perspective.
Source: Value in Health - December 1, 2022 Category: International Medicine & Public Health Authors: C Nguyen, MMH Lahr, DJ Van der Zee, H Van Voorst, YBWEM Roos, M Uyttenboogaart, E Buskens Source Type: research

P64 NIMBUS geometric clot extractor for tough clots: SPERO study results and clot composition
ConclusionsIn challenging cases with tough clot, first pass of NIMBUS retrieved clot richer in fibrin and lower in RBC content than clot retrieved with the first pass of standard MT devices.ReferencesFennell VS, Setlur Nagesh SV, Meess KM, Gutierrez L, James RH, Springer ME, Siddiqui AH. What to Do about Fibrin Rich ‘Tough Clots’? Comparing the Solitaire Stent Retriever with a Novel Geometric Clot Extractor in an in vitro Stroke Model. J Neurointerv Surg 2018 Sep;10(9):907–910. DOI: 10.1136/Neurintsurg-2017-013507. EPUB 2018 Jan 19. PMID: 29352061. Do you have any conflict of interest to declare?: YesConf...
Source: Journal of NeuroInterventional Surgery - August 29, 2022 Category: Neurosurgery Authors: van den Berg, R., Ribo, M., Arnberg, F., Estrade, L., Thornton, J., Tomasello Weitz, A., Gontu, V., Karam, A., Hernandez, D., Clarencon, F., Buhk, J.-H., Wiesmann, M., Nouri, N., Bricout, N., Desal, H., Januel, A., Doyle, K., Liebeskind, D., Brouwer, P., Tags: 14th Congress of the European Society of Minimally Invasive Neurological Therapy 2022 Meeting Abstracts Source Type: research

Influence of Onset to Imaging Time on Radiological Thrombus Characteristics in Acute Ischemic Stroke
Conclusion: In our population of acute ischemic stroke patients, we found no clear association between onset-to-imaging time and radiological thrombus characteristics. This suggests that elapsed time from stroke onset plays a limited role in the interpretation of radiological thrombus characteristics and their effect on treatment results, at least in the early time window.
Source: Frontiers in Neurology - June 18, 2021 Category: Neurology Source Type: research

Effect of anticoagulant therapy in COVID-19 patients
CONCLUSION: Analysis of the literature showed that there was insufficient evidence to answer our objective on the effect of anticoagulation on outcome in COVID-19 patients, especially due to the low scientific quality of the described studies. Randomised controlled studies are needed to answer this question.PMID:33861430 | DOI:10.1007/s12471-021-01574-7
Source: Netherlands Heart Journal - April 16, 2021 Category: Cardiology Authors: R G Tieleman F A Klok E Belfroid J Hoogervorst-Schilp I Schalkers C W Jansen H J Siebelink Source Type: research

Impact of different anticoagulation management strategies on outcomes in atrial fibrillation: Dutch and Belgian results from the GARFIELD-AF registry.
CONCLUSIONS: In GARFIELD-AF, despite similar characteristics, patients on anticoagulants were treated differently in NL and BE. Although the rate of major bleeding was 33% higher in NL, variations in bleeding, mortality and TE rates were not statistically significant. PMID: 32886853 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - September 3, 2020 Category: Hematology Authors: Seelig J, Hemels MEW, Xhaët O, Bongaerts MCM, de Wolf A, Groenemeijer BE, Heyse A, Hoogslag P, Voet J, Herrman JR, Vervoort G, Hermans W, Wollaert B, Boersma LVA, Hermans K, Lucassen A, Verstraete S, Adriaansen HJ, Mairesse GH, Terpstra WF, Faes D, Piete Tags: J Thromb Haemost Source Type: research

Reasons for discontinuation of novel oral anticoagulant therapy in patients with atrial fibrillation.
Conclusion: DOAC discontinuation rates varied significantly and appeared related to drug-specific side effects, patient-initiated discontinuation, and bleeding. We observed longer-term administration of apixaban, suggesting that this drug is better tolerated than dabigatran or rivaroxaban. PMID: 32011180 [PubMed - as supplied by publisher]
Source: Current Medical Research and Opinion - February 5, 2020 Category: Research Tags: Curr Med Res Opin Source Type: research

Older age and duration of exposure to type 2 diabetes in selective screening of asymptomatic carotid artery stenosis for primary stroke prevention —A single institution experience
Carotid artery disease is a well-known cause of stroke. In Malaysia, stroke is the third most common cause of death [1]. To our knowledge, there is still limited information regarding stroke and its associated risk factors. Strokes from ischemic infarction of the brain is due to narrowing or occlusion from local thrombosis or embolization of a proximal thrombus. The incidence of ischemic stroke from carotid artery stenosis in an asymptomatic western population is approximately 2.7% according to a report from Netherlands by Hartog et al.
Source: Primary Care Diabetes - November 16, 2019 Category: Primary Care Authors: Lenny Suryani Safri, Henry Tan Chor Lip, M. Iqbal Saripan, Tan Jih Huei, K. Krishna, Mohamad Azim Md Idris, Hanafiah Harunarashid Tags: Original research Source Type: research

Canagliflozin Inhibits Human Endothelial Cell Proliferation and Tube Formation
In conclusion, the present study identified canagliflozin as a potent inhibitor of human EC proliferation. The anti-proliferative action of canagliflozin is observed in ECs isolated from both the venous and arterial circulation, and is partly due to the blockade of cyclin A expression. In addition, this study found that canagliflozin inhibits tube formation in cultured ECs and mouse aortic rings. Notably, these actions are specific for canagliflozin and not seen with other SGLT2 inhibitors. The ability of canagliflozin to exert these pleiotropic effects on EC function may contribute to both the adverse and salutary actions...
Source: Frontiers in Pharmacology - April 15, 2019 Category: Drugs & Pharmacology Source Type: research

Flow Patterns in Carotid Webs: A Patient-Based Computational Fluid Dynamics Study EXTRACRANIAL VASCULAR
CONCLUSIONS: Carotid webs are associated with increased recirculation zones and regional increased wall shear stress metrics that are associated with disturbed flow. These findings suggest that a carotid web might stimulate thrombus formation, which increases the risk of acute ischemic stroke.
Source: American Journal of Neuroradiology - April 10, 2019 Category: Radiology Authors: Compagne, K. C. J., Dilba, K., Postema, E. J., van Es, A. C. G. M., Emmer, B. J., Majoie, C. B. L. M., van Zwam, W. H., Dippel, D. W. J., Wentzel, J. J., van der Lugt, A., Gijsen, F. J. H., for the MR CLEAN investigators Tags: EXTRACRANIAL VASCULAR Source Type: research

Rivaroxaban for non-valvular atrial fibrillation and venous thromboembolism in the Netherlands: a real-world data based cost-effectiveness analysis.
CONCLUSIONS: In patients with NVAF or VTE, rivaroxaban treatment is likely to be cost-effective and potentially cost-saving alternative to VKA in the Netherlands. PMID: 30614320 [PubMed - as supplied by publisher]
Source: Journal of Medical Economics - January 8, 2019 Category: Health Management Tags: J Med Econ Source Type: research

Design and rationale of the Edoxaban Treatment in routiNe clinical prActice for patients with Atrial Fibrillation in Europe (ETNA-AF-Europe) study
This study details the design of the Edoxaban Treatment in routiNe clinical prActice for patients with Atrial Fibrillation in Europe (ETNA-AF-Europe) study – a postauthorization observational study, which is part of the postapproval plan for edoxaban agreed with the European Medicines Agency. Methods The ETNA-AF-Europe study (Clinicaltrials.gov: NCT02944019) is a multicenter, prospective, observational study that enrolled 13 980 patients with atrial fibrillation treated with edoxaban from 852 sites across 10 European countries (Austria, Belgium, Germany, Ireland, Italy, the Netherlands, Portugal, Spain, Switzerland,...
Source: Journal of Cardiovascular Medicine - January 3, 2019 Category: Cardiology Tags: Research articles: Trial design Source Type: research